You Asked. We Listened.
This updated aqueous ophthalmic preparation was refined in collaboration with select customers to optimize drop performance, consistency, and handling. Survey participants reported:
- Smooth, controlled dosing, with 3 out of 4 users saying the bottle pressure was "just right."
- Nearly 9 in 10 observed drops forming as expected and staying in the eye during administration.
- Nearly two-thirds rated the new formula better than our previous tacrolimus option.
- No foaming observed before and during dosing in the majority of uses.
- The majority (over 80%) reported no side effects after dosing.
These insights guided targeted improvements to formulation characteristics and packaging design.
Fill out the form below to join our waitlist and be the first to know when this new formulation is available for purchase.
The first 200 orders will get a 20% discount!
Quality You Can Count On
Backed by full stability studies and positive user feedback, our improved Tacrolimus Aqueous Ophthalmic Formulation delivers precision and consistency from start to finish.
Every batch is produced in our FDA-registered 503B Outsourcing Facility, upholding the highest manufacturing standards to ensure quality in every preparation.
Beyond-Use Dating (BUD)
The initial BUD for this formulation is 90 days, based on current completed stability data. As ongoing stability testing continues, the BUD may be extended as validated data allows, ensuring that practices can rely on up-to-date, evidence-supported product dating. Each batch will include clear labeling to reflect the most current verified BUD information.